Systemic Sclerosis Market Size, Competitive Landscape and Market Forecast - 2029

SKU: DMPH32 | Last Updated On: Jun 13 2022 | Available Formats

> Global Systemic Sclerosis Market Expected to reach a high CAGR of 6.0% during the forecast period 2022-2029: DataM Intelligence

Global Systemic Sclerosis Market is segmented By Type (Limited, Diffuse), By Drug Type (Corticosteroids, Immunosuppressive Agents, Endothelin Receptor Agonists, Calcium Channel Blockers, Phosphodiesterase 5 Inhibitors, Chelating Agents, Prostacyclin Analogues, H2 Blockers, Proton Pump Inhibitors, ACE Inhibitors), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2022-2029


Market Overview

The Global Systemic Sclerosis Market is expected to grow at a CAGR of 6.0% during the forecasting period (2022-2029).

  • Systemic sclerosis (SSc) is a systemic connective tissue disease of unknown etiology that affects the skin, blood vessels, muscles, joints, and a variety of internal organs, such as the digestive tract, heart, lungs, and kidneys.

  • The global Systemic sclerosis treatment market is estimated to reach USD 1.4 million by 2024.

Market Growth

  • Primary market drivers include increased use of expensive biologics, the rise in clinical trials for systemic sclerosis, high acceptance of new therapies by patients, and new drug approvals.

  • However, delay in diagnosis and lack of safe and effective treatments will restrain the market growth.

Market Segmentation

  • The Global Systemic sclerosis market report segments the market by type, drug type, and region.

  • Based on the extent of skin involvement, the market is segmented into Limited cutaneous systemic sclerosis (lcSSc), or limited scleroderma, and Diffuse cutaneous systemic sclerosis (dcSSc), or diffuse scleroderma.

  • Limited cutaneous systemic sclerosis is the more common type of SSc.

  • Based on drug type, the market is segmented into Corticosteroids, Immunosuppressive Agents, Endothelin Receptor Agonists, Calcium Channel Blockers, PDE-5 Inhibitors, Chelating Agents, Prostacyclin Analogues, H2 Blockers, Proton Pump Inhibitors, and ACE Inhibitors.

  • Regarding the drug category, the segment of immunosuppressive agents is expected to retain dominance over the forecast period.

  • Regionally, the market is segmented into five major regions, namely North America, South America, Europe, Asia Pacific, and RoW.

  • North America will dominate the market. The US has an annual incidence of about 20 cases per 1 million adults.

Scope of the Report

  • The report profiles the following companies of Systemic sclerosis market – Actelion, Roche/Genentech, BMS, Allergan, GSK, Biogen, Novartis, Teva, MedImmune, Celgene, Chugai, ASTA, Aspen, Pfizer, Eli Lilly, Bayer, and many more.

By Type

  • Limited

  • Diffuse

By Drug Type

  • Corticosteroids

  • Immunosuppressive Agents

  • Endothelin Receptor Agonists

  • Calcium Channel Blockers

  • Phosphodiesterase 5 Inhibitors

  • Chelating Agents

  • Prostacyclin Analogues

  • H2 Blockers

  • Proton Pump Inhibitors

  • ACE Inhibitors

By Region

  • Asia Pacific (China, Japan, India, Australia, Rest of Asia Pacific)

  • Europe (Germany, France, The UK, Italy, Spain, Rest of Europe)

  • North America (The USA, Canada, Mexico)

  • South America (Brazil, Argentina, Rest of South America)

  • Rest of the World

Trending Topics

Astragalus Polysaccharide Market

Immunosuppressants Drugs Market

Remote Patient Monitoring Market

Did not find what you were looking for?Every 7 out of 10 customers request tailored reports. Get yours today!
We collate your requirements.
Our global research team is put into action.
We deliver, and make sure your endeavour is a success!

Buy This Report

20% Discount Applied*

Note*: For "Bundle/Bulk" Subscription of Reports,
please contact: [email protected]

Get your free sample proposal with a single click!